Development of prostate specific antigen (PSA) screening nomograms for 15-year prediction of prostate cancer diagnosis (PCDx), mortality (PCM), and all-cause mortality (ACM)doi:10.1016/s1569-9056(18)31116-3S. CarlssonM. BrooksA. Zajichek...
The risk assessment tool helps determine whether a prostate biopsy is necessary when PSA screening is ambiguous.